CUMULATIVE INDEX Volume 18, Numbers 1-12, Pages 1-96 January 1999—December 1999

A

abciximab, 9:67

ablation, catheter, 4:31

ACE inhibitors, 8:62

acute MI, 2:12, 9:65, 12:93

adenosine, 4:28

alcohol consumption, 10:79

American College of Cardiology, 5:33, 6:41

American Heart Association, 12:89

amiodarone, 2:9, 11:83

angina, 1:1, 1:3

angiogenesis, 2:10

angiographic predictors, 6:46

angioplasty, 9:65

primary, 9:67

antiarrhythmics, 5:37

anticoagulants, 6:47

aortic debris, 6:47

arrhythmias

atrial, 9:68

ventricular, 2:12

ASD, 2:14

aspirin, 8:62

atherectomy

rotational, 3:17

atrial arrhythmias, 9:68

atrial fibrillation, 2:9, 7:55, 8:59, 12:92

nonvalvular, 6:44

AVID, 12:95

B

BEST, 12:90

beta blockers, 1:3, 3:18

bundle branch block, 1:4

C

CABG Patch, 5:38

calcium blockers, 12:94

cardiac arrest, 10:76, 11:83

cardiac death, 10:79

cardiac surgery, 10:78

cardiomyopathy

dilated, 7:53

cardioversion, 8:59, 10:77

catheter ablation, 4:31

CHF, 7:53

cholesterol, 3:20

LDL, 8:63

CLASICS, 5:37

coenzyme Q, 7:53

constrictive pericarditis, 2:15

coronary

disease, 6:45, 8:63

stenting, 7:49

syndromes, 4:30

CPR

ACD, 10:76

standard, 10:76

C-reactive protein, 10:75

D

defibrillators

implantable, 5:37

defibrillator shocks

implantable, 8:60

digoxin, 9:72

diltiazem, 1:3

dofetilide, 11:86

DSE, 9:71

E

ELITE II, 12:91

endocardial mapping, 1:7

EPS, 7:55

estrogen, 10:75

echocardiography

dobutamine stress, 4:27

exercise, 7:50

transesophageal, 2:11, 7:51

F

Framingham Heart Study, 3:22

FRISC II, 5:35

H

heart failure, 2:9, 3:18

congestive, 11:86

hirudin, 4:30

HOPE study, 12:89

I

ibutilide, 8:59, 9:68

ICDs, 7:53, 9:70

immune system activation, 1:1

implantable

defibrillators, 5:37

defibrillator shocks, 8:60

L

LDL cholesterol, 8:63

left ventricle, 1:7

LV dilation, 2:13

M

Merit-Heart Failure, 6:41

MI, 6:46, 9:72

acute, 2:12, 9:65, 12:93

MR, 3:21, 4:29

MUSTT, 6:42

MVP, 8:57

myopathy, 12:94

N

nonvalvular atrial fibrillation, 6:44

O

obesity, 11:87

open artery hypothesis, 1:6

OPUS, 5:36

P

pericarditis

constrictive, 2:15

PET, 9:71

polyunsaturated fatty acids

marine, 10:73

protein

C-reactive, 10:75

PTCA, 12:93

pulmonary venous flow reversal, 4:29

Q

QT, 10:77

R

recurrent syncope, 12:91

renin-angiotensin access, 11:84

reperfusion, 9:65

restenosis, in-stent, 3:17, 3:19

S

SHOCK, 5:33

sotalol, 7:55, 8:60

stenting, coronary, 7:49

stroke, 3:20, 10:78

stroke prevention, 12:92

superior vena cava Doppler, 2:15

surveillance systems, 9:70

SVT, 4:28

syncope, 3:23, 7:53

recurrent, 12:91

T

tachycardia, ventricular, 1:4, 6:43

thrombocytopenia

heparin-induced, 10:75

thrombolysis, 9:67

thrombolytic therapy, 12:93

tilt table training, 12:91

TMLR, 4:25

TMR, 11:81

transcatheter closure, 2:14

trials

American College of Cardiology, 5:33, 6:41

American Heart Association, 12:89

AVID, 12:95

BEST, 12:90

CABG Patch, 5:38

CLASICS, 5:37

ELITE II, 12:91

FRISC II, 5:35

Merit-Heart Failure, 6:41

MUSTT, 6:42

OPUS, 5:36

SHOCK, 5:33

U

ultrasound predictors

angiographic, 3:19

intravascular, 3:19

V

ventricle

left, 1:7

ventricular arrhythmias, 2:12

vitamin E, 10:73